Level C· Early human research exploring benefitsProspective StudyEurope PMCOpen access

Low Circulating Levels of Omentin-1 and Irisin in Type 2 Diabetes Mellitus Patients with Metabolic-Associated Fatty Liver Disease

Li HY., Zhang YY., Cai XM., Chen X.

Prospective Study with a reported sample of 80 on Type 2 Diabetes, published in Turk J Gastroenterol (2025) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Turk J Gastroenterol (2025)
Reported sample size
80
Source database
Europe PMC
PMID
40241486
PMCID
PMC12257686
DOI
10.5152/tjg.2025.24639
Citations
1

Abstract (original English)

Background/aims The study analyzed the roles of circulating omentin-1 and irisin in patients with type 2 diabetes mellitus (T2DM) concomitant with metabolic-associated fatty liver disease (MAFLD). Materials and methods This cross-sectional study included 80 patients with T2DM but no MAFLD, 62 patients with MAFLD but no T2DM, 50 T2DM patients having MAFLD (T2DM/MAFLD), and 80 healthy individuals. Results The serum levels of omentin-1 and irisin were both significantly reduced in patients with T2DM coexisting with MAFLD compared to T2DM or MAFLD patients alone. In T2DM patients, the level of omentin-1 decreased as the level of fasting plasma glucose (FPG) increased and the level of high-density lipoprotein cholesterol (HDL-C) reduced; the level of irisin decreased as the levels of FPG and fasting insulin (FINS) increased. In MAFLD patients, a lower level of omentin-1 was correlated with a lower level of HDL-C but with a greater waist-to-hip ratio (WHR), alanine aminotransferase and aspartate aminotransferase levels; a lower level of irisin was correlated with higher WHR and FINS level. In patients with T2DM coexisting with MAFLD, those with a lower level of omentin-1 were found to have a lower level of HDL-C concurrent with lower WHR and triglyceride level; and those with a lower level of irisin showed lower WHR, FPG and FINS levels. Combined evaluation of omentin-1 and irisin fo

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
HumansFatty LiverDiabetes Mellitus, Type 2InsulinAlanine TransaminaseAspartate AminotransferasesBlood GlucoseFibronectinsLectinsCytokines

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research